PT-141 (Bremelanotide) and Apixaban Interaction

Why This Combination Comes Up

Patients prescribed apixaban for atrial fibrillation or venous thromboembolism may also seek bremelanotide for hypoactive sexual desire disorder (HSDD) or off-label erectile dysfunction. The question is straightforward: does bremelanotide change how apixaban works, or does apixaban change how bremelanotide works? Based on current pharmacology data, the answer to both is no. But the clinical picture has nuance worth understanding.

Two Different Patient Populations, One Overlapping Concern

Apixaban use skews toward patients over 60 with cardiovascular comorbidities. Bremelanotide was approved for premenopausal women, but off-label use in men and postmenopausal women is increasing through telehealth and compounding pharmacies. When these populations overlap, prescribers face a scenario with limited published data on the specific drug pair.

Why Prescribers Should Still Pay Attention

The absence of a documented interaction is not the same as proven safety. Bremelanotide's cardiovascular effects (transient hypertension, heart rate changes) add a pharmacodynamic layer that matters in patients already managing vascular risk factors with apixaban 1.

Pharmacokinetic Profile of Bremelanotide

Bremelanotide (brand name Vyleesi) is a cyclic heptapeptide melanocortin-4 receptor agonist. The FDA approved it in June 2019 specifically for HSDD in premenopausal women, at a dose of 1.75 mg administered subcutaneously at least 45 minutes before anticipated sexual activity 1.

How Bremelanotide Is Cleared

Unlike most small-molecule drugs, bremelanotide is a peptide. Its primary elimination route is hydrolysis into inactive peptide fragments, not hepatic cytochrome P450 metabolism. The FDA label states that in vitro studies showed bremelanotide did not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations 1. It also did not induce CYP1A2, CYP2B6, or CYP3A4.

P-glycoprotein and Transporter Data

The bremelanotide label does note one transporter-related interaction: it slowed gastric emptying and reduced the Cmax of orally administered drugs in clinical pharmacology studies. Naltrexone Cmax decreased by approximately 24% and indomethacin Cmax decreased by approximately 28% when co-administered with bremelanotide 1. This effect is relevant to apixaban absorption, though the clinical significance is likely modest.

Pharmacokinetic Profile of Apixaban

Apixaban (Eliquis) is a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa. It was approved by the FDA for stroke prevention in non-valvular atrial fibrillation and for treatment and prevention of venous thromboembolism 2.

CYP3A4 and P-gp: The Two Gatekeepers

Apixaban is metabolized primarily by CYP3A4, with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2J2. It is also a substrate of P-gp and breast cancer resistance protein (BCRP). The FDA label contains specific dose-reduction guidance for patients taking strong dual inhibitors of CYP3A4 and P-gp (ketoconazole, itraconazole, ritonavir, clarithromycin) and recommends avoiding co-administration with strong dual inducers like rifampin 2.

What Triggers an Apixaban Dose Change

The threshold is clear in the label: only strong dual inhibitors of both CYP3A4 and P-gp require a dose reduction from 5 mg to 2.5 mg twice daily. Single-pathway inhibitors (affecting CYP3A4 alone or P-gp alone) do not require adjustment. In the ARISTOTLE trial (N=18,201), apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% versus warfarin, with a major bleeding rate of 2.13% per year versus 3.09% for warfarin 3.

Interaction Analysis: Bremelanotide + Apixaban

The interaction question breaks into two domains: pharmacokinetic (does one drug change the blood levels of the other?) and pharmacodynamic (do their combined effects on the body create additive risk?).

Pharmacokinetic Assessment

Bremelanotide does not inhibit or induce CYP3A4. It does not inhibit P-gp. By the criteria in the apixaban label, bremelanotide does not meet the threshold for any dose adjustment. The only pharmacokinetic consideration is the gastric-emptying effect. Bremelanotide slows gastric motility, which could delay apixaban absorption and reduce its peak concentration 1. A lower Cmax with preserved overall exposure (AUC) could theoretically blunt the peak anticoagulant effect, but this has not been studied for the specific pair. Given that apixaban has a relatively flat concentration-effect curve at therapeutic doses, this delay is unlikely to be clinically meaningful for most patients.

Pharmacodynamic Assessment

This is where clinical attention is warranted. Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg (and up to 8 mmHg in some studies), typically peaking 2 to 3 hours after injection and resolving within 12 hours 1. The bremelanotide label carries a specific warning: it is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

Patients on apixaban often carry diagnoses like atrial fibrillation, prior DVT/PE, or post-surgical VTE prophylaxis. Many of these patients also have hypertension, coronary artery disease, or heart failure. The transient BP spike from bremelanotide, while modest in isolation, adds hemodynamic stress in a population already managing vascular risk. The concern is not a drug-drug interaction in the traditional sense. It is a drug-disease interaction layered on top of anticoagulation.

Severity Classification

No major drug interaction database (Lexicomp, Micromedex, Clinical Pharmacology) lists a direct interaction between bremelanotide and apixaban as of May 2026. Using standard DDI classification frameworks, this pair would fall into a "no known interaction" or "monitor" category based on the theoretical gastric-emptying effect and the pharmacodynamic BP concern 4.

Blood Pressure Monitoring Protocol

For patients using both drugs, a structured monitoring approach reduces risk without requiring drug discontinuation.

Baseline and Per-Dose Checks

Measure blood pressure before the first co-administered dose. Recheck at 2 hours post-injection (the expected bremelanotide Tmax) and again at 12 hours. If systolic BP exceeds 160 mmHg or diastolic exceeds 100 mmHg at any check, bremelanotide should be withheld until cardiovascular status is reassessed. The Endocrine Society's 2019 clinical practice guidelines on female sexual dysfunction note that cardiovascular screening should precede any pharmacotherapy for HSDD in patients with vascular comorbidities 5.

Ongoing Monitoring

After the first three uses, if blood pressure remains stable (systolic <140 mmHg), patients can transition to periodic home monitoring with a validated cuff. Document readings in a log for the prescribing clinician. No INR or anti-Xa monitoring is needed specifically for this combination, as bremelanotide does not affect coagulation pathways.

Dose Adjustment Considerations

No dose adjustment to either drug is required based on the current pharmacokinetic data.

Bremelanotide Dosing

The standard dose remains 1.75 mg subcutaneously, no more than 8 doses per month, no more than 1 dose per 24 hours 1. There is no basis to reduce this dose because of apixaban co-administration.

Apixaban Dosing

The standard dose remains 5 mg twice daily (or 2.5 mg twice daily for patients meeting at least two of these criteria: age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or greater). Bremelanotide does not meet the strong dual CYP3A4/P-gp inhibitor threshold that would trigger the dose reduction 2.

Patient Counseling Points

Clear communication reduces both anxiety and risk when patients take these medications together.

Timing Separation

While not pharmacokinetically required, separating bremelanotide injection and the nearest apixaban dose by 2 to 3 hours may minimize any theoretical impact of delayed gastric emptying on apixaban absorption. This is a conservative recommendation, not an evidence-based mandate.

Warning Signs to Report

Patients should contact their prescriber if they experience severe headache within hours of bremelanotide injection, visual disturbances, chest pain, or any signs of unusual bleeding (prolonged nosebleeds, blood in urine or stool, excessive bruising). The AVERROES trial (N=5,599) established that even in aspirin-intolerant AF patients, apixaban's bleeding profile remained favorable, but individual risk varies based on comorbidities and concurrent medications 6.

Alcohol and Nausea

Bremelanotide causes nausea in approximately 40% of patients at the 1.75 mg dose, per the RECONNECT phase 3 trials (N=1,247) 7. Alcohol worsens both nausea and the hypotensive rebound that can follow the initial BP spike. For patients on apixaban, vomiting within 1 to 2 hours of an oral apixaban dose could reduce drug absorption and compromise anticoagulation.

Special Populations

Renal Impairment

Apixaban dose adjustment in renal impairment follows the label criteria (serum creatinine 1.5 mg/dL or greater, combined with age or weight factors). Bremelanotide has not been studied in severe renal impairment (eGFR <30 mL/min) and is not recommended in that population 1. Patients with moderate renal impairment using both drugs should have renal function checked every 3 to 6 months.

Hepatic Impairment

Apixaban is contraindicated in severe hepatic impairment (Child-Pugh C). Bremelanotide has not been studied in hepatic impairment. For patients with mild hepatic impairment (Child-Pugh A) using both agents, no dose adjustments are needed, but liver function tests should be reviewed at baseline 2.

Older Adults

The intersection of these medications in patients over 65 raises practical concerns. Bremelanotide's cardiovascular warning becomes more significant in older patients with higher baseline BP and stiffer vasculature. Apixaban clearance decreases modestly with age. A conservative approach in this population is to begin bremelanotide under direct observation at the first dose, with vital signs taken at baseline, 1 hour, and 3 hours post-injection.

Other Bremelanotide Drug Interactions Worth Knowing

Bremelanotide's interaction profile is narrow, but two documented interactions deserve mention for completeness.

Naltrexone

Co-administration reduced naltrexone Cmax by 24% via the gastric-emptying mechanism. For patients using low-dose naltrexone alongside bremelanotide and apixaban, the three-drug combination has no established PK interaction, but the cumulative nausea burden may be significant 1.

Antihypertensives

The bremelanotide label warns that the transient BP increase may be less predictable in patients taking antihypertensives. For apixaban patients who are also on ACE inhibitors, ARBs, or calcium channel blockers, the net hemodynamic effect of adding bremelanotide is harder to predict. Close monitoring at initiation is warranted 8.

Bottom Line for Prescribers

No pharmacokinetic interaction between bremelanotide and apixaban has been identified through in vitro CYP/transporter studies, clinical pharmacology data, or post-marketing surveillance. The combination does not require dose adjustment to either drug. The clinically relevant concern is pharmacodynamic: bremelanotide's transient blood pressure elevation in a population that is, by definition, managing cardiovascular risk. Monitor blood pressure at the first co-administered dose, counsel patients on warning signs, and document the clinical rationale for prescribing both agents in patients with known cardiovascular disease.